Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: Successful treatment with defibrotide [7]

British Journal of Haematology

Volumn 123, Issue 4, 2003, Pages 752-753

  Saviola, Alessia ^a   Luppi, Mario ^a   Potenza, Leonardo ^a   Morselli, Monica ^a   Ferrari, Angela ^a   Riva, Giovanni ^a   Torelli, Giuseppe ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Defibrotide; Gemtuzumab ozogamicin; Leukaemia; Mylotarg; Veno occlusive disease

Indexed keywords

DEFIBROTIDE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANAMNESIS; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE COURSE; HUMAN; LABORATORY TEST; LETTER; LIVER VENOOCCLUSIVE DISEASE; MEDICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA, MYELOID; PLATELET AGGREGATION INHIBITORS; POLYDEOXYRIBONUCLEOTIDES; TIME FACTORS;

EID: 0344553533     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04667.x     Document Type: Letter

References (8)

1. Cohen, A.D., Luger, S.M., Sickles, C., Mangan, P.A., Porter, D.L., Schuster, S.J., Tsai, D.E., Nasta, S., Gewirtz, A.M. & Stadtmauer, E.A. (2002) Gemtuzumab ozogamicin monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplantation, 30, 23-28.
2. Giles, J.F., Kantarjian, H.M., Kornblau, S.M., Thomas, D.A., Garcia-Manero, G., Waddelow, T.A., David, C.L., Phan, A.T., Colburn, D.E., Rashid, A. & Estey, E.H. (2001) Mylotarg therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413.
3. Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadmauer, E.A., Sievers, E.L., Mineur, P., Bennett, J.M., Berger, M.S., Eten, C.B., Munteanu, M., Loken, M.R., Van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. Mylotarg Study Group (2002a) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 16, 1627-1636.
4. Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Lowenberg, B., Estey, E., Dombret, H., Theobald, M., Voliotis, D., Leopold, L.H., Richie, M., Brger, M.S., Sherman, M.L. & Appelbaum, F.R. Mylotarg Study Group (2002b) A final analysis of the efficacy and safety of gemtuzumab ozogamicin in 277 patients with acute myeloid leukemia in first relapse. Blood, 100, 1312a.
5. Rajvanshi, P., Shulman, H.M., Sievers, E.L. & McDonald, G.B. (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy. Blood, 99, 2310-2314.
6. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Esten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. Mylotarg Study Group (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
7. Wadleigh, M., Richardson, P.G., Zahrieh, D., Lee, S.J., Cutler, C., Ho, V., Alyea, E.P., Antin, J.H., Stone, R.M., Soiffer, R.J. & DeAngelo, D.J. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 8.
8. Zein, N., Sinha, A.M., McGahren, W.J. & Ellestad, G.A. (1988) Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, 1198-1201.